Chemoinformaics analysis of Salvileucantholide
| Molecular Weight | 350.326 | nRot | 1 |
| Heavy Atom Molecular Weight | 336.214 | nRig | 28 |
| Exact Molecular Weight | 350.079 | nRing | 6 |
| Solubility: LogS | -4.168 | nHRing | 4 |
| Solubility: LogP | 4.043 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 40 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 1 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 11 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 11 |
| nHA | 6 | APOL | 47.5471 |
| nHD | 0 | BPOL | 22.7249 |
| QED | 0.532 |
| Synth | 4.828 |
| Natural Product Likeliness | 1.609 |
| NR-PPAR-gamma | 0.899 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.121 |
| Pgp-sub | 0.011 |
| HIA | 0.012 |
| CACO-2 | -4.949 |
| MDCK | 0.0000145 |
| BBB | 0.009 |
| PPB | 0.981647 |
| VDSS | 1.567 |
| FU | 0.0431766 |
| CYP1A2-inh | 0.242 |
| CYP1A2-sub | 0.163 |
| CYP2c19-inh | 0.389 |
| CYP2c19-sub | 0.069 |
| CYP2c9-inh | 0.799 |
| CYP2c9-sub | 0.105 |
| CYP2d6-inh | 0.262 |
| CYP2d6-sub | 0.181 |
| CYP3a4-inh | 0.503 |
| CYP3a4-sub | 0.221 |
| CL | 5.625 |
| T12 | 0.251 |
| hERG | 0.052 |
| Ames | 0.194 |
| ROA | 0.972 |
| SkinSen | 0.215 |
| Carcinogencity | 0.76 |
| EI | 0.131 |
| Respiratory | 0.962 |
| NR-Aromatase | 0.948 |
| Antiviral | Yes |
| Prediction | 0.760534 |